Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

LivaNova (NASDAQ:LIVN) Investors: Needham Reaffirms Buy Rating, Sees $97.0/Share

Needham Analyst Rating Change LivaNova NASDAQ:LIVN

LivaNova (NASDAQ:LIVN) Rating Maintained

In an analyst note released on Tuesday morning, Livanova (NASDAQ:LIVN) stock Buy was reiterated by Needham. They currently have a $97.0 target price per share on the stock. Needham’s target price per share gives a potential upside of 31.26 % from the company’s last stock close price.

NASDAQ:LIVN is at the moment trading -0.64% lower at $44.79 as of 4:05 AM New York time. LivaNova’s stock is 0% over the last 200 days. It has underperformed the S&P500, which has added 6.00% over the same time.

LIVN Stock Chart

LivaNova (NASDAQ:LIVN) Profile

LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing.

LivaNova (NASDAQ:LIVN) traded down -0.64% on 5 December, hitting $44.79. A total of 525,721 shares of the company’s stock traded hands. This is up from average of 359,580 shares. LivaNova has a 52 week low of $44.76 and a 52 week high of $65.68. The company has a market cap of $2.18B and a P/E ratio of 0.

Get the latest LivaNova (NASDAQ:LIVN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post LivaNova (NASDAQ:LIVN) Investors: Needham Reaffirms Buy Rating, Sees $97.0/Share appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

LivaNova (NASDAQ:LIVN) Investors: Needham Reaffirms Buy Rating, Sees $97.0/Share


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription